Full report can be viewed by visiting: http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-week-of-august-6-imsc-amrn-ssh-lptn-mric-sgyp-trov-ctso-celh-irwd-bsx-si-pfe-hgsi-gsk-dndn-fsx-clsp-fb-znga-ge-jcp-dis-m
Sometimes all it takes is a spark. In the global economic climate, there are still concerns about the viability of the Euro Zone, the price of oil still hinges on the outcome of numerous geopolitical situations in the Middle East and the signs are few that the US economy is healthy enough to move forward without facing the threat of recession again.
An encouraging jobs report, however, showed that US businesses were hiring on a pace quicker than most expected and that was enough to provide the spark that ignited the DOW on a run of over two hundred points and a close above the 13,000 mark again. The rally was helped by encouraging words from the European Central Bank that indicated help is on its way to the ailing economies, specifically the banks.
Pivotal Play For August:
Implant Sciences (IMSC): Implant Sciences has made encouraging strides in the field of explosive trace detection (ETD) and global security against terrorism for the better part of the year, but a key date discussed in numerous company reports over the past few months has indicated that a huge milestone may be coming due this month as the Transportation Security Administration (TSA) is set to decide on whether to approve Implant's Quantum Sniffer (QS) ETD technology for inclusion on the Administration's list of qualified products. Such a move would position this relatively small company to take advantage of a booming market and to potentially land very notable government contracts as an imminent TSA mandate has contractors scrambling to meet the December 3rd deadline of ensuring that 100% of all air cargo destined for the United States be screened for explosives.
Healthcare, Biotech, Pharmaceutical:
Amarin Corporation (AMRN): Shares of Amarin had been on the decline since the FDA approved Vascepa (AMR-101) for the treatment of very high triglycerides during the closing the days of July, but investors will look towards Friday's rally and last week's late action as a potential sign of a reversal that could reignite interest in the stock and send shares rallying back towards the twenty dollar mark. AMRN closed the day Friday up by over three percent at just under the twelve dollar mark.
Sunshine Heart (SSH): Shares of Sunshine Heart have recently pulled back into territory that could be considered a good second chance for investors that may have missed the run from roughly three dollars to over seventeen during the past couple of months. In fact, given that Sunshine now has an approved product in Europe, this one could be considered even more of an intriguing success story than before.
Lpath Inc. (LPTN): Shares of Lpath have continuously moved higher over the past weeks as the expected re-start of halted trials could launch shares back to previously-traded levels. Trials were halted earlier in the year when conflicts surfaced related to the company's finish/fill contractor and had no bearing on the effectiveness of Lpath's treatments. A new finish/fill contractor was quickly identified and the continuation of the trials is expected to take place within the current quarter, providing investors with an imminent catalyst.
MRI Interventions (MRIC): MRI Interventions, like Sunshine, is another company in the sector that may be providing investors with a second chance to get in following impressive price runs. MRI ran from the dollar level just months ago to a recent high of five as volume flew into trading based on the company's ClearPoint and ClearTrace technologies which augment a hospital's existing MRI suite to simplify normally highly-intrusive surgeries of the brain and heart, respectively.
Synergy Pharmaceuticals (SGYP): Synergy Pharmaceuticals is yet another company in the biotech/small pharma sector that has seen its share price sink to once-again very attractive levels. This company has numerous key catalysts pending that could quickly reverse the retreating trend, namely the release of decisive trial results later this year that would give reason to believe that the SGYP market cap could quickly approach that of competitor Ironwood Pharmaceuticals (IRWD), which sits at well over a billion dollars.
TrovaGene Inc (TROV): Shares of TrovaGene have also retreated of late, although the company's growing portfolio of developing diagnostic tests that would - if previous successes are repeated - prove to be able to detect numerous cancer types and various infectious diseases by identifying specific transrenal DNA and RNA originating from normal and diseased cell death in urine.
Facebook (FB) and Zynga (ZNGA): Both company's continued their respective downward trends last week following earnings reports that failed to impress during previous week and it's likely - especially if the broad markets suffer - that the new 52-week lows will be breached yet again, with prices dropping even lower.
Healthy Food and Beverage:
Celsius Holdings (CELH): Last week's volume spike makes shares of Celsius Holdings again worthy of the stock watch list. Although still limping along in terms of increasing investor interest, the company has made some strides this year at stabilizing its cash flow and the logical next step would be to capitalize on the renewed PR push while also expanding sales beyond the $2.5 million number registered last quarter. While two days of heavy trading last week hardly marks a trend, those two days eclipsed the total number of shares previously traded for the entire month of July.
Contact VFC's Stock House: firstname.lastname@example.org
Originally published at: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: http://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFCs Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.